

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2696)*

INSIDE INFORMATION ANNOUNCEMENT

COMPLETION OF THE H SHARE FULL CIRCULATION

This announcement is made by Shanghai Henlius Biotech, Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 24 March 2025, 9 June 2025, 16 January 2026 and 19 January 2026 (the “**Announcements**”) in relation to the consideration and approval of the proposed implementation of the H Share Full Circulation by the Board, the completion of the filing made by the Company with the CSRC in relation to the proposed implementation of the H Share Full Circulation, as well as the listing approval granted by the Stock Exchange for the H Share Full Circulation. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE H SHARE FULL CIRCULATION

The Board is pleased to announce that, the conversion of an aggregate of 182,645,856 Unlisted Shares into H Shares was completed on 4 February 2026 and the listing of such Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on 5 February 2026.

SHAREHOLDING STRUCTURE

The shareholding structure of the Company immediately before and upon the completion of the Conversion and Listing is set out below:

Type of Shares	Immediately before completion of the Conversion and Listing		Immediately upon completion of the Conversion and Listing	
	Number of Shares (shares)	Approximate percentage of the total number of issued shares of the Company (%)	Number of Shares (shares)	Approximate percentage of the total number of issued shares of the Company (%)
Unlisted Shares	380,066,312	69.93	197,420,456	36.32
H Shares	163,428,541	30.07	346,074,397	63.68
Total	<u>543,494,853</u>	<u>100</u>	<u>543,494,853</u>	<u>100</u>

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares and other securities of the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 4 February 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan, Dr. Yi Liu and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Ruilin Song and Mr. Yihao Zhang as the independent non-executive directors.